Alaunos Therapeutics
TCRT
92 hedge funds and large institutions have $204M invested in Alaunos Therapeutics in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 25 reducing their positions, and 17 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 25
32% more call options, than puts
Call options by funds: $4.85M | Put options by funds: $3.68M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 96 → 92 (-4)
20% less capital invested
Capital invested by funds: $255M → $204M (-$51.2M)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.02M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$828K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$411K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.31M |
| 3 |
Barclays
London,
United Kingdom
|
-$2.54M |
| 4 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$1.8M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.69M |
TCRT Hedge Fund Activity: Q2 2014 in Review
92 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2014, worth a combined $204M — down 20% from $255M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TCRT and 13 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 34 added.
The largest buyer was Vanguard Group, adding an estimated $1.18M. The largest seller was Fidelity Investments, cutting an estimated $11.3M.
- 92 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2014, down from 96 in Q1 2014.
- Funds reported $204M of Alaunos Therapeutics stock for Q2 2014, down 20% quarter-over-quarter.
- 13 funds opened new Alaunos Therapeutics positions in Q2 2014 and 17 closed out, a net change of -4 holders.
- The largest Alaunos Therapeutics buyer in Q2 2014 was Vanguard Group, an estimated $1.18M added.
- The largest Alaunos Therapeutics seller in Q2 2014 was Fidelity Investments, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2014.